Showing results (481-490 of 539) with videos related to

Sort By:
Pageof 54
Annals of the Rheumatic Diseases|December 7, 2014
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)Raphaèle Seror, Hendrika Bootsma, Alain Saraux, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaisonChiara Baldini, Laurent Arnaud, Tadej Avčin, et al.
Lupus Science & Medicine|September 22, 2016
Off-label use of rituximab for systemic lupus erythematosus in EuropeMonica Rydén-Aulin, Dimitrios Boumpas, Irene Bultink, et al.
Annals of the Rheumatic Diseases|May 1, 2019
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39Athina Spiliopoulou, Marco Colombo, Darren Plant, et al.
Annals of the Rheumatic Diseases|October 29, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|November 19, 2020
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trialRenaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, et al.
RMD Open|July 27, 2026
Characteristics and outcomes of anti-Ku antibody-associated interstitial lung disease: a retrospective study of 60 patientsMarie Robert, Yann Nguyen, Marie-Pierre Debray, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 28, 2016
Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid ArthritisJing Cui, Dorothee Diogo, Eli A Stahl, et al.
Annals of the Rheumatic Diseases|June 17, 2025
Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)Simon J Bowman, Raphaele Seror, Raphael Porcher, et al.
Clinical and Experimental Rheumatology|August 30, 2019
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patientsSoledad Retamozo, Nihan Acar-Denizli, Astrid Rasmussen, et al.
Pageof 54